FDA approves first drug, Infilbray, for neurological problems in Gaucher

Once-daily oral treatment OK'd for adults and children with type 3 disease

Written by Marisa Horak MS |

The words

The oral med venglustat is now approved in the U.S., under the brand name Infilbray, for treating the neurological manifestations of Gaucher type 3. (Image from iStock)

The U.S. Food and Drug Administration (FDA) has approved Infilbray (venglustat) as the first-ever treatment indicated to address the neurological manifestations of Gaucher disease type 3.

Developed by Sanofi, the once-daily oral medication was specifically approved for adults and children with type 3 disease who weigh at least 15 kg (33 pounds). In a late-stage clinical trial, the drug led to significant improvements among treated patients on assessments of cognition and ataxia, a motor coordination problem.

Until now, while people with Gaucher type 3 had medication options for managing the non-neurological symptoms of the disease, no treatments were available to address its neurological complications. As a result, neurological symptoms could continue to progress even when systemic disease manifestations were being managed.

In the Phase 3 LEAP2MONO trial (NCT05222906), Infilbray was shown to be significantly better than Cerezyme (imiglucerase) — an approved treatment for non-neurological symptoms of Gaucher types 1 or type 3 — at improving the two key measures of neurological function. Meanwhile, the data also showed that Infilbray was as good as Cerezyme at controlling key non-neurological symptoms.

“With Infilbray, we are delivering a breakthrough in care by addressing the neurological symptoms of Type 3 Gaucher disease, a milestone which reflects our deep commitment to innovation for patients and is made possible by our dedicated team who work to address their unmet medical needs,” Manuela Buxo, executive vice president, global head of specialty care at Sanofi, said in a company press release announcing the FDA’s approval.

“Sanofi has brought novel medicines to people living with rare diseases for decades, and [this] US approval of Infilbray for Type 3 Gaucher disease patients is an important addition to our broad portfolio,” Buxo added.

Recommended Reading
Mice explore laboratory equipment in this drawing.

Neurological issues ease with gene therapy in Gaucher mouse model

A rare genetic disease, Gaucher is marked by a deficiency of glucocerebrosidase, known as GCase — an enzyme that’s needed to break down certain fatty molecules in cells. When the enzyme is lacking or does not work properly, these substances build to toxic levels in cells, causing tissue damage that ultimately drives disease symptoms.

Gaucher is divided into three main types based on the presence, or lack thereof, and severity of neurological symptoms. Individuals with type 1 have no neurological symptoms, while those with type 2 experience severe neurological issues that appear shortly after birth and progress rapidly. Type 3, for its part, is defined by milder neurological problems that develop later in childhood and progress more slowly.

Nonprofit CEO calls Infilbray ‘a long-awaited advancement’

Aviva Rosenberg, CEO and cofounder of the Gaucher Community Alliance, a U.S. nonprofit, said Infilbray’s approval “marks a long-awaited advancement” for those experiencing the disease’s “devastating neurological symptoms.”

“Patients living with Type 3 Gaucher disease face a long and difficult road to accurate diagnosis, often going years without answers while neurological manifestations progress,” Rosenberg said.

Until this year, people with type 3 Gaucher had no treatments specifically approved for their condition and relied on the off-label use of enzyme replacement therapies (ERTs) approved for type 1 disease. That changed in January, when the FDA extended approval of Cerezyme, also marketed by Sanofi, to include the treatment of non-neurological symptoms in children and adults with type 3.

We have been able to treat the systemic manifestations of Type 3 Gaucher disease, while the neurological manifestations remained beyond the reach of available therapies. … [The approval] represents a major milestone for patients.


ERT works by supplying a functional version of the GCase enzyme to replace the defective enzyme. However, the replacement enzyme cannot adequately pass from the bloodstream into the brain, which limits its ability to address the neurological manifestations of the disease.

Infilbray is a substrate reduction therapy (SRT) that inhibits an enzyme called glucosylceramide synthase, which is needed for producing the fatty substances that toxically accumulate in people with Gaucher. By blocking this enzyme, the therapy aims to reduce the buildup of the fatty molecules and ease disease symptoms.

Unlike the enzyme in Cerezyme, Infilbray is a small molecule that can enter the brain, allowing it to target disease-related processes in the brain as well as elsewhere in the body.

“We have been able to treat the systemic manifestations of Type 3 Gaucher disease, while the neurological manifestations remained beyond the reach of available therapies,” said Pramod Mistry, MD, PhD, director of the Lysosomal Disease Center and Gaucher Disease Treatment Center at the Yale School of Medicine in Connecticut.

“The availability of a medicine capable of addressing the neurological manifestations of this devastating disorder represents a major milestone for patients, families, and the global Type 3 Gaucher disease community,” Mistry said.

Recommended Reading
A dropper squirting blood is seen next to four half-filled vials.

Gaucher treatment doesn’t normalize key biomarker levels

Therapy now under review in Europe, other regions

Infilbray’s approval in the U.S. was supported by data from the LEAP2MONO trial, which enrolled 43 adults and adolescents with Gaucher type 3 who had stable non-neurological manifestations while on ERT. The participants, ages 12 and older, were randomly assigned to either continue on Cerezyme or receive once-daily oral Infilbray for one year.

The results showed that Infilbray was better than Cerezyme on a combined assessment of neurological function that measured cognitive ability and difficulty with coordination and balance. Meanwhile, the treatments had comparable effects on key systemic manifestations, including spleen and liver volume.

The study’s open-label extension is now ongoing, with further results expected to provide information about the longer-term effects of Infilbray.

According to its prescribing information, the most common side effects of Infilbray include gastrointestinal symptoms as well as adverse effects on mood. The medication also carries warnings noting that Infilbray may cause suicidal thoughts and behaviors, clouding of vision in younger patients, and harm a developing fetus when the drug is taken during pregnancy.

The therapy is now being reviewed in the European Union, Japan, and other regions, and Sanofi said it plans to submit additional applications in other countries around the world through 2027.